GB8906796D0 - Method of enhancing neutralising antibody activity in human or animal sera or in other body secretions - Google Patents

Method of enhancing neutralising antibody activity in human or animal sera or in other body secretions

Info

Publication number
GB8906796D0
GB8906796D0 GB898906796A GB8906796A GB8906796D0 GB 8906796 D0 GB8906796 D0 GB 8906796D0 GB 898906796 A GB898906796 A GB 898906796A GB 8906796 A GB8906796 A GB 8906796A GB 8906796 D0 GB8906796 D0 GB 8906796D0
Authority
GB
United Kingdom
Prior art keywords
enhancing
human
antibody activity
neutralising antibody
body secretions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB898906796A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDICAL RESEARCH International
Original Assignee
MEDICAL RESEARCH International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDICAL RESEARCH International filed Critical MEDICAL RESEARCH International
Priority to GB898906796A priority Critical patent/GB8906796D0/en
Publication of GB8906796D0 publication Critical patent/GB8906796D0/en
Priority to GB9006608A priority patent/GB2229725B/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Neutralising antibody activity is enhanced by exposure of the antibody to an enhancing factor comprising or extracted from human or animal saliva or an enzyme for the digestion of carbohydrates which is not inimical to the neutralising antibody, for example amylase or lysozyme, in an antibody activity enhancing amount.
GB898906796A 1989-03-23 1989-03-23 Method of enhancing neutralising antibody activity in human or animal sera or in other body secretions Pending GB8906796D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB898906796A GB8906796D0 (en) 1989-03-23 1989-03-23 Method of enhancing neutralising antibody activity in human or animal sera or in other body secretions
GB9006608A GB2229725B (en) 1989-03-23 1990-03-23 A method of enhancing neutralising antibody activity in human or animal sera or in other body secreations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898906796A GB8906796D0 (en) 1989-03-23 1989-03-23 Method of enhancing neutralising antibody activity in human or animal sera or in other body secretions

Publications (1)

Publication Number Publication Date
GB8906796D0 true GB8906796D0 (en) 1989-05-10

Family

ID=10653944

Family Applications (2)

Application Number Title Priority Date Filing Date
GB898906796A Pending GB8906796D0 (en) 1989-03-23 1989-03-23 Method of enhancing neutralising antibody activity in human or animal sera or in other body secretions
GB9006608A Expired - Fee Related GB2229725B (en) 1989-03-23 1990-03-23 A method of enhancing neutralising antibody activity in human or animal sera or in other body secreations

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB9006608A Expired - Fee Related GB2229725B (en) 1989-03-23 1990-03-23 A method of enhancing neutralising antibody activity in human or animal sera or in other body secreations

Country Status (1)

Country Link
GB (2) GB8906796D0 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551760A1 (en) 2003-01-02 2004-07-22 Pedersen Medical A/S Antimicrobial composition for local use on mucosal membranes and skin

Also Published As

Publication number Publication date
GB2229725B (en) 1993-02-17
GB2229725A (en) 1990-10-03
GB9006608D0 (en) 1990-05-23

Similar Documents

Publication Publication Date Title
FR12C0004I2 (en) ANTIBODIES TO HUMAN CTLA-4 ANTIGEN AND USE
EP0365685A4 (en) Freeze-dried composition containing enzyme-labeled antihuman interferon-_g(b) antibody and enzymatic immunoassay kit containing the composition
HU892558D0 (en) Process and preparation for the induction of a joint
DK0909388T3 (en) Immunological assay for spongiform encephalopathies
EP0204989A3 (en) Use of penicillamine in the treatment of immune deficiency diseases
PH31198A (en) Protein recognized by antibodies raised against native P28 of schitosoma mansoni.
GB8906796D0 (en) Method of enhancing neutralising antibody activity in human or animal sera or in other body secretions
FI881122A (en) Method for isolating basement membrane proteins from human and animal tissues
SE9903534L (en) Carrier containing a major capsid protein L1 from human papillomavirus and its use
JPS5615215A (en) Preparation of human immunoglobulin for intravenous injection with immobilized pepsin gel
GB2003887A (en) Isolation of peptides from urine
DE69027441D1 (en) Ribozymenhemmer
AU1948788A (en) Expression of immunologically active proteins of human b-lymphotropic virus
AU590712B2 (en) Immune interferon and method for its purification
GR3015489T3 (en) Monoclonal antibodies and process for the diagnosis of phytophtora infections.
SE8500340D0 (en) ANTIBODY PREPARATION AND WAY TO PREPARE AND SET TO USE IT
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof
EP0070167A3 (en) Hypertension treatment
ES2085937T3 (en) ENZYMATIC DESACILATION OF ACIL-AMINOSORBOSE AND ITS USE IN THE MANUFACTURE OF 1-DEOXYNOYRIMYCIN.